The study of the antiulcer activity of biofiton® “healthy stomach” on acute alcohol-prednisolone stomach ulcer in rats

Authors

  • O. A. Kolisnyk College of the National University of Pharmacy, Ukraine
  • O. G. Chistyakov Scientific and Production Pharmaceutical Company “AIM”, LLC, Ukraine
  • S. M. Drogovoz National University of Pharmacy, Ukraine
  • A. Yu. Pozdniakova National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/cphj.14.1312

Keywords:

phytotherapy, gastric ulcer, antiulcer activity

Abstract

Improvement of the methods of extraction of biologically active substances from the plant raw material is one of the forms of herbal drugs optimization. When treating gastric ulcer it is expedient to use the complex therapy oriented to neutralization of hydrochloric acid in the stomach, protection of its mucous membrane against aggressive factors, reduction of inflammation and acceleration of reparative processes. In this regard drugs of herbal origin are the most promising; it is stipulated by their high activity in combination with low toxicity. The subject of the study is biofiton® “Healthy stomach” tablets produced by Chistyakov herbalist shop; they contain althea roots (13%), cinquefoil rhizomes (11%), plantain leaves (11%), licorice roots (11%), motherwort herb (11%), yarrow herb (11%), marigold flowers (10%), camomile flowers (10%), calamus rhizomes (9%). This phytodrug has been made with the help of the unique modern technology of cryomechanic activation of the plant raw material, which is completely different from all known methods of extraction of biologically active substances. This technology gives the opportunity to concentrate the main properties of the herbal drugs of different biochemical nature in a small volume. The aim of this study is to prove the antiulcer activity of biofiton® “Healthy stomach”. The antiulcer activity of the drug has been studied in the dose of 120 mg/kg (calculated with the help of the coefficient of species sensitivity) on the model of acute alcoholic prednisolone gastric ulcer in rats. As a result, the antiulcer activity of biofiton® “Healthy stomach” has been proven experimentally and is 75.5%; practically it is equal to the activity of the reference drug ranitidin, which antiulcer activity is 85.1%. Therefore, high efficacy of biofiton® “Healthy stomach” makes it promising for prevention of the recurrence and in complex treatment of gastric ulcer.

References

Анисенкова А.Ю. Факторы риска и клинические проявления ишемической болезни сердца у женщин с различной степенью поражения коронарных артерий: Дис. … канд. мед. наук. – С.Пб., 2006. – 126 с.

Беленичев И.Ф., Мазур И.А., Кучеренко Л.И. Фармакология: Коллективная научная монография. – Новосибирск: Изд-во «СибАК», 2013. – 194 с.

Горева Л.А. Острый инфаркт миокарда у больных сахарным диабетом 2 типа: эффективность и безопасность зофеноприла и периндоприла, включая влияние на состояние оксидативного стресса и эндотелиальную функцию: Дис. … д-ра мед. наук. – М., 2012. – 102 с.

Коняхин А.Ю. Современные патогенетические подходы к коррекции ишемии миокарда: Автореф. дис. … д-ра мед. наук. – М., 2007. – 47 с.

Лойт А.О., Савченков М.Ф. Профилактическая токсикология: Руководство для токсикологов-экспериментаторов. – Иркутск: Изд-во Иркут. ун-та, 1996. – 288 с.

Мазур И.А., Волошин Н.А., Визир В.А., Беленичев И.Ф. Тиотриазолин, тиодарон в лечении сердечно-сосудистой патологии. – Запорожье: Печатный мир, 2011. – 303 с.

Пат. №2404974 РФ, МПК C 07 D 249/08 (2006.01), A 61 P 9/04 (2006.01), A 61 P 9/10 (2006.01), A 61 P 9/12 (2006.01). Бромид 1-(β-фенилэтил)-4-амино-1,2,4-триазолия (МТ), обладающий кардиопротективным, противоишемическим, антигипертензивным, антиоксидантным, протеин-синтетическим и энерготропным действием / И.А.Мазур, И.Ф.Беленичев, Ю.М.Колесник, Л.И.Кучеренко, Н.А.Волошин, А.В.Абрамов, И.С.Чекман, Н.А.Горчакова, М.И.Загородний, В.И.Мамчур, Р.С.Довгань, Г.В.Георгиевский; заявитель и патентообладатель – ООО «НПО «Фарматрон». – №2008148765.

– Заявл.: 10.12.2008. Опубл.: 27.11.2010.

Пат. №92692 Україна, МПК A 61 K 31/41, C 07 D 249/00, A 61 P 9/00, A 61 K 9/20, A 61 K 9/08. Лікарський засіб для лікування ішемічної хвороби серця та гіпертонічної хвороби / І.А.Мазур, І.Ф.Бєленічев, Ю.М.Колесник, Л.І.Кучеренко, М.А.Волошин, А.В.Абрамов, І.С.Чекман, Н.О.Горчакова, М.І.Загородній, В.Й.Мамчур, Р.С.Довгань, Г.В.Георгієвський; заявник і патентовласник – ТОВ «НВО «Фарматрон». – №a200906983. – Заявл.: 03.07.2009. Опубл.: 25.11.2010. – Бюл. №22.

Рекомендації Української асоціації кардіологів з профілактики артеріальної гіпертензії: Посібник з Національної програми профілактики артеріальної гіпертензії. – 2004. – 83 с.

Рылова А.К., Розанов А.В. // Сердце. – 2008. – №4. – С. 190-196.

Стефанов А.В. Доклинические исследования лекарственных средств. – К.: Авиценна, 2002. – 568 с.

Трешкур Т.В. // Вестник аритмол. – 2002. – №30. – С. 31-39.

Bakris G.L. // JAMA. – 2013. – Vol. 292, №11. – Р. 2227-2236.

Expert consensus document on b-adrenergic receptor blocers. The task force on beta-blocers of European Society of Cardiology // Eur. Heart. J. – 2011. – Vol. 25. – P. 1341-1362.

Packer M. // N. Engl. J. Med. – 2011. – Vol. 31, №344 (22). – Р. 1651-1658.

Shaddy R. // JAMA. – 2011. – Vol. 298, №9. – Р. 1171-1179.

White W. Blood pressure monitoring in cardiovascular medicine and therapeutscs. – New Jersey: Humana Press, 2010. – 308 p.

Downloads

Published

2014-09-12

Issue

Vol. 18 No. 3 (2014)

Section

Pre-clinical studies of new drugs

License

Copyright (c) 2014 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).